Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1519505/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846171270505299968 |
|---|---|
| author | Lu Li Shilei Yang Fengqi Fang Li Tian Ying He Jia Li Yanwei Chen Deshi Dong |
| author_facet | Lu Li Shilei Yang Fengqi Fang Li Tian Ying He Jia Li Yanwei Chen Deshi Dong |
| author_sort | Lu Li |
| collection | DOAJ |
| format | Article |
| id | doaj-art-7d013f6d4a1f4a17a4770467fbbfcbad |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-7d013f6d4a1f4a17a4770467fbbfcbad2024-11-11T04:39:25ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-11-011510.3389/fphar.2024.15195051519505Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in ChinaLu Li0Shilei Yang1Fengqi Fang2Li Tian3Ying He4Jia Li5Yanwei Chen6Deshi Dong7Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, Chinahttps://www.frontiersin.org/articles/10.3389/fphar.2024.1519505/fullHER-2-positive metastatic breast cancernetwork meta-analysiscost-effectiveness analysispyrotinib plus capecitabineT-DM1T-DXd |
| spellingShingle | Lu Li Shilei Yang Fengqi Fang Li Tian Ying He Jia Li Yanwei Chen Deshi Dong Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China Frontiers in Pharmacology HER-2-positive metastatic breast cancer network meta-analysis cost-effectiveness analysis pyrotinib plus capecitabine T-DM1 T-DXd |
| title | Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China |
| title_full | Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China |
| title_fullStr | Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China |
| title_full_unstemmed | Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China |
| title_short | Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China |
| title_sort | corrigendum the value of second line anti her2 therapy in metastatic her 2 positive patients a cost effectiveness analysis in china |
| topic | HER-2-positive metastatic breast cancer network meta-analysis cost-effectiveness analysis pyrotinib plus capecitabine T-DM1 T-DXd |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1519505/full |
| work_keys_str_mv | AT luli corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina AT shileiyang corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina AT fengqifang corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina AT litian corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina AT yinghe corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina AT jiali corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina AT yanweichen corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina AT deshidong corrigendumthevalueofsecondlineantiher2therapyinmetastaticher2positivepatientsacosteffectivenessanalysisinchina |